Physician profile
Eric M Rishe
NPI 1023133550
$27,330.43
in general payments reported to CMS, 2019-2025
61 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,751 · 2021: $3,496 · 2022: $2,116 · 2023: $2,633 · 2024: $1,396 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,768 · Education: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,767.96 |
| Education | $305.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $14,890.78 | 2019-2020 | |
| Janssen Biotech, INC. | $1,633.52 | 2020-2025 | Darzalex, Tecvayli, Talvey |
| E.R. Squibb & Sons, L.L.C. | $1,263.05 | 2020-2025 | Opdivo, Reblozyl, Opdualag |
| Pfizer INC. | $872.89 | 2019-2025 | |
| Macrogenics, INC. | $818.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $651.90 | 2020-2023 | |
| Celgene Corporation | $581.55 | 2020-2024 | Reblozyl, Pomalyst |
| Genzyme Corporation | $551.49 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $544.76 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $540.68 | 2020-2024 | Lynparza, Tagrisso, Calquence |
| Rigel Pharmaceuticals, INC. | $507.44 | 2020-2024 | Rezlidhia, Tavalisse |
| Lilly USA, LLC | $389.26 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $388.06 | 2022-2025 | Venclexta |
| Glaxosmithkline, LLC. | $371.55 | 2021-2025 | Ojjaara, Shingrix, Blenrep |
| Incyte Corporation | $353.47 | 2020-2023 | Jakafi |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Rishe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.